In the previous couple of months, the UN’s World Well being Group (WHO) could have come down strongly on a number of Indian drug manufacturing corporations for not sustaining high quality, however its perception within the Indian nationwide auditor—the Comptroller and Auditor Common of India’s (CAG) functionality and professionalism stays steely.
As soon as once more, the colourful ‘India story’ resonated strongly on the worldwide stage in Geneva on Monday. Already holding the year-long chair for the more and more essential Shanghai Cooperation Organisation (SCO) and the G20, India’s CAG has been voted to be the exterior auditor for the World Well being Group (WHO), Geneva, for a four-year time period from 2024 to 2027.
Much more than the results of the voting, what’s noteworthy right here is the overwhelming measurement of the mandate. An awesome majority—114 out of whole 156 votes or 73 per cent of the member nations —voted for India’s re-election.
“The overwhelming variety of nations that voted for India is unprecedented in WHO’s elections for an exterior auditor. It speaks of the popularity of India’s standing apart from the fame and perception in CAG’s professionalism, excessive requirements, and world audit expertise,” mentioned Parveen Mehta, deputy CAG, who together with the CAG Girish Chandra Murmu and a crew of delegates is in Geneva for the election and the 76th World Well being Meeting.
An official launch mentioned that “CAG is already holding this place in WHO since 2019, for a four-year time period from 2019 to 2023.”
“That is the second main worldwide audit project for the CAG this 12 months following his choice for the put up of Exterior Auditor (2024-2027) of Worldwide Labour Group (ILO) in Geneva earlier this 12 months in March 2023,” it added.
In addition to WHO, the CAG is at present the exterior auditor of Meals and Agriculture Group (2020-2025), Worldwide Atomic Power Company (2022-2027), Group for Prohibition of Chemical Weapons (2021-2023) and Inter-Parliamentary Union (2020-2022).
In latest months, a number of Indian drug manufacturing corporations have earned WHO’s ire as a result of high quality management points.
India-made cough syrup manufacturers have reportedly claimed the lives of 66 very younger youngsters in The Gambia final 12 months.
On October 5, 2022, the WHO issued an alert headlined ‘Substandard (contaminated) paediatric medicines recognized in WHO area of Africa’ the place it named a number of Indian corporations exporting ‘substandard’ medicines.
After which once more on January 11, 2023, WHO issued a product alert towards India-made cough syrups that allegedly claimed the lives of 18 youngsters in Uzbekistan.